BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors. 2022

Wenwen Nie, and Yang Lu, and Chenghao Pan, and Jian Gao, and Mengxin Luo, and Jiaming Du, and Jiao Wang, and Peihua Luo, and Hong Zhu, and Jinxin Che, and Qiaojun He, and Xiaowu Dong
Hangzhou Institute of Innovative Medicine, Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, PR China.

Fibroblast growth factor receptor 4 (FGFR4) together with co-receptors modulate the activation of downstream proteins that regulate fundamental processes, and elevated FGFR4 activity is associated with Hepatocellular Carcinoma (HCC). Hence, FGFR4 is a promising therapeutic target for HCC. Based on BLU9931, we designed and synthesized a series of phenylquinazoline derivatives as novel inhibitors of FGFR4 through the covalent reversible strategy. Among them, a novel compound (C3) showed FGFR4 and cell proliferation inhibitory activity. Cellular mechanism studies demonstrated that compound C3 induced apoptosis via the FGFR4 signaling pathway blockage. Further mechanism study showed that C3 has the reversible covalent binding capacity, could be used as a reference for the development of novel FGFR4 covalent reversible inhibitors.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D051499 Receptor, Fibroblast Growth Factor, Type 4 A fibroblast growth factor receptor that is mainly expressed in LUNG; KIDNEY; PANCREAS; and SPLEEN. It also plays an important role in SKELETAL MUSCLE development and can contribute to NEOPLASTIC CELL TRANSFORMATION. Fibroblast Growth Factor Receptor 4,Fibroblast Growth Factor Receptors 4,Receptor 4, Fibroblast Growth Factor

Related Publications

Wenwen Nie, and Yang Lu, and Chenghao Pan, and Jian Gao, and Mengxin Luo, and Jiaming Du, and Jiao Wang, and Peihua Luo, and Hong Zhu, and Jinxin Che, and Qiaojun He, and Xiaowu Dong
Design, synthesis and biological evaluation of phosphoroxy quinazoline derivatives as potential EGFRT790M/C797S inhibitors.
July 2023, Bioorganic & medicinal chemistry,
Wenwen Nie, and Yang Lu, and Chenghao Pan, and Jian Gao, and Mengxin Luo, and Jiaming Du, and Jiao Wang, and Peihua Luo, and Hong Zhu, and Jinxin Che, and Qiaojun He, and Xiaowu Dong
Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.
March 2024, European journal of medicinal chemistry,
Wenwen Nie, and Yang Lu, and Chenghao Pan, and Jian Gao, and Mengxin Luo, and Jiaming Du, and Jiao Wang, and Peihua Luo, and Hong Zhu, and Jinxin Che, and Qiaojun He, and Xiaowu Dong
Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.
April 2021, European journal of medicinal chemistry,
Wenwen Nie, and Yang Lu, and Chenghao Pan, and Jian Gao, and Mengxin Luo, and Jiaming Du, and Jiao Wang, and Peihua Luo, and Hong Zhu, and Jinxin Che, and Qiaojun He, and Xiaowu Dong
Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.
February 2022, Journal of medicinal chemistry,
Wenwen Nie, and Yang Lu, and Chenghao Pan, and Jian Gao, and Mengxin Luo, and Jiaming Du, and Jiao Wang, and Peihua Luo, and Hong Zhu, and Jinxin Che, and Qiaojun He, and Xiaowu Dong
Design, synthesis and biological evaluation of novel quinazoline derivatives as immune checkpoint inhibitors.
May 2024, Bioorganic & medicinal chemistry letters,
Wenwen Nie, and Yang Lu, and Chenghao Pan, and Jian Gao, and Mengxin Luo, and Jiaming Du, and Jiao Wang, and Peihua Luo, and Hong Zhu, and Jinxin Che, and Qiaojun He, and Xiaowu Dong
Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.
March 2022, Journal of medicinal chemistry,
Wenwen Nie, and Yang Lu, and Chenghao Pan, and Jian Gao, and Mengxin Luo, and Jiaming Du, and Jiao Wang, and Peihua Luo, and Hong Zhu, and Jinxin Che, and Qiaojun He, and Xiaowu Dong
Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants.
October 2023, European journal of medicinal chemistry,
Wenwen Nie, and Yang Lu, and Chenghao Pan, and Jian Gao, and Mengxin Luo, and Jiaming Du, and Jiao Wang, and Peihua Luo, and Hong Zhu, and Jinxin Che, and Qiaojun He, and Xiaowu Dong
Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.
December 2021, Bioorganic chemistry,
Wenwen Nie, and Yang Lu, and Chenghao Pan, and Jian Gao, and Mengxin Luo, and Jiaming Du, and Jiao Wang, and Peihua Luo, and Hong Zhu, and Jinxin Che, and Qiaojun He, and Xiaowu Dong
Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents.
August 2012, Journal of enzyme inhibition and medicinal chemistry,
Wenwen Nie, and Yang Lu, and Chenghao Pan, and Jian Gao, and Mengxin Luo, and Jiaming Du, and Jiao Wang, and Peihua Luo, and Hong Zhu, and Jinxin Che, and Qiaojun He, and Xiaowu Dong
Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.
April 2021, ACS medicinal chemistry letters,
Copied contents to your clipboard!